Skip to content

The Intersectional Viborg Screening Program: Cost-(Effectiveness) of Screening for Diabetes and Cardiovascular Diseases

Intersectional Screening Program for Diabetes and Cardiovascular Diseases Among 67-years Old Citizens of the Municipal of Viborg

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03395509
Acronym
VISP
Enrollment
4500
Registered
2018-01-10
Start date
2014-08-01
Completion date
2029-08-01
Last updated
2024-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Aortic Aneurysm, Abdominal, Arrythmia, Carotid Atherosclerosis, Diabetes, Hypertension, Mass Screening, Peripheral Arterial Disease

Keywords

Mass screening, cardiovascular disease, diabetes

Brief summary

This is an intersectional and interdisciplinary screening program in Viborg Municipality, including 67 years old citizens. This observational study will estimate the cost-effectiveness of a combined screening program for the following conditions: Abdominal aortic aneurysm, peripheral arterial disease, carotid plaque, hypertension, arrhythmia, and type-2-diabetes. Furthermore, the incidence of the outlined conditions will be described and so will the result of the intervention initiated (secondary medical prophylaxis, smoking cessation, introduction to nutritionally deficient diet etc.)

Detailed description

Description of the cohort: All Viborg municipality citizen are invited to the combined screening program around there 67th birthday. Participants with positive screening results are offered following up consultations and prophylactic interventions are initiated (secondary medical prophylaxis, smoking cessation, introduction to nutritionally deficient diet etc.) 67 years-old citizens from the surrounding municipalities without the offer of the combined screening are used as a control group (1 case: 5 controls). There are no exclusion criteria. The screening examination includes: Blood pressure in both arms, ankle brachial blood pressure index (ABI), ultrasound for carotid plaque and abdominal aortic aneurysm, HbA1c and pulmonary function test. Furthermore, a questionnaire on lifestyle parameters, BMI, medical history, walking-related pain and self-rated quality of life (EQ-5D). One year after the screening examination, the participants will receive a questionnaire in order to evaluate the effect from a participant perspective. The cost(-effectiveness) of the screening program will be estimated after 5 years based on prevalence of diseases, response rate, data extraction from nationwide registries and existing evidence of disease prevention.

Interventions

None listed

Sponsors

Odense University Hospital
CollaboratorOTHER
Central Jutland Regional Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
67 Years to 67 Years
Healthy volunteers
Yes

Inclusion criteria

All Viborg municipality citizen are invited to the combined screening program around there 67th birthday.

Exclusion criteria

There are no

Design outcomes

Primary

MeasureTime frameDescription
Baseline prevalence of diabetesInclusion will take place from sep. 2014 to sep. 2020Bedside HbA1c
Baseline prevalence of peripheral arterial disease (PAD) in men and women aged 67 years from a population screening study on the Municipal of Viborg.Inclusion will take place from sep. 2014 to sep. 2020Ankel Brachial Index
Baseline prevalence of abdominal aortic aneurysm (AAA)Inclusion will take place from sep. 2014 to sep. 2020Ultra sound examination (AP diameter (mm))
Baseline prevalence of carotic plaquesInclusion will take place from sep. 2014 to sep. 2020Ultra sound examination of A. carotis (IMT in mm)
Baseline prevalence of hypertensionInclusion will take place from sep. 2014 to sep. 2020BP(mmhg)
Baseline prevalence of cardiac arrythmiaInclusion will take place from sep. 2014 to sep. 2020ECG

Secondary

MeasureTime frameDescription
The cost(-effectiveness) of the screening program5 years after ending inclusionSocio-economic evaluation (national register data), QALY

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026